2023 Biotech Charity Contest Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2023 Biotech Charity Contest

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: DewDiligence_on_SI who wrote (100)	5/5/2023 12:19:07 AM
From: Aloner	Read Replies (1) of 233

Hey Dew, forgive my ignorance, but why do you feel an RS is in order by MGTA? What would that serve? I have so many questions on this since DNTH is currently privately held, like what is their book value? I know they have $180M in cash, which is reassuring. How many shares are currently outstanding? What will the listing price be? How will that be determined? If the value of my MGTA position was $10,000 at the time of the NASDAQ ticker transition, do I then get roughly 21.3% in DNTH? Will the de-listing and listing occur simultaneously? I've only been investing for 45 years, but this is all new to me. Now I've had 2 M&A in a Month. The above are all rhetorical questions, but if you or anyone else has a definitive answer, I'm very curious. And the future CVR (Contingent Value Rights) is a bit confusing as well, although I doubt there will be any cash forthcoming, unless they can sell the Aeron Chairs. This seems like a pretty good deal from the MGTA side considering the SUSAR event in January. Thank you all for any insight. Humbly, ALONER

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next